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Summary
  Introduction:  Folic acid (FA) may delay the formation of atherosclerotic lesions. Increased plasma levels of 
von Willebrand factor (VWF) are observed in cardiovascular disease, which leads to higher risk 
of thrombosis. Fibrinogen (Fb) is a well-documented risk factor of cardiovascular disease. The 
aim of this study was to analyze the effect of FA supplementation on the Fb, VWF and C-reactive 
protein (CRP) plasma concentrations in subjects with atherosclerosis risk factors.
  Material/Methods:  The study enrolled 124 Caucasian individuals (60 M, 64 F) with atherosclerosis risk factors – 
family history of premature ischaemic stroke, arterial hypertension, dyslipidaemia, overweight 
and obesity, cigarette smoking and low physical activity. The participants were asked to take FA 
in the low dose of 0.4 mg/24 h for three months.
  Results:  After FA supplementation a significant reduction of the VWF concentrations in females (76.6 
vs 72.3%; p=0.028) and in males (75.5 vs 66.9%; p=0.001) was observed. Among women and 
men with dyslipidaemia concentrations of VWF decreased after FA supplementation (76.8% vs 
69.6%; p=0.003 and 76.7% vs 67.8%; p=0.001 respectively). Among females and males with BMI 
≥25 kg/m2 concentrations of VWF decreased only in men (77.6% vs 66.5%; p=0.001). In fema-
le and male smokers supplementation of FA decreased VWF concentrations (82.5% vs 74.4%; 
p=0.012 and 76.6% vs 69.5%; p=0.036 respectively).
  Discussion:  The results of our study suggest that there is an effect of FA supplementation on VWF concen-
trations in subjects with atherosclerosis risk factors.
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       -               -               -               -               -       IntroductIon
Numerous reports confirm preventive effects of folic acid 
(FA) on developmental birth defects, Alzheimer’s disease, 
megaloblastic anaemia and depressive disorders [18,21]. 
There is no consensus among researchers on the preventive 
effect of FA on cardiovascular disease. It has been shown 
that, through lowering of homocysteine (Hcy) concentra-
tions in the blood, FA may delay the formation of athero-
sclerotic lesions [1]. The report by Brown et al. indicates 
that even a slight FA deficiency promotes atherosclerosis 
formation in arterial endothelium [54]. However, large-sca-
le clinical trials have shown that a preventive use of FA in 
individuals with established cardiovascular disease or with 
history of myocardial infarction was not associated with 
a lower risk of new cardiovascular events [2,3,4,17,28].
Increased concentration of fibrinogen (Fb) promotes hy-
percoagulability and incidents of thrombosis, leading to 
myocardial infarction, stroke or critical limb ischaemia. It 
is classified as an acute-phase protein; therefore Fb levels 
may also be elevated in inflammation [27]. Fibrinogen is 
a well-documented risk factor of cardiovascular disease 
[13]. However, results of studies on the association of FA 
with coagulation factors are ambiguous. Liem et al. re-
ported lack of association of FA supplementation with Fb 
concentration [15]. Nevertheless, other reports indicate a 
beneficial anticoagulative effect of FA through decreasing 
concentration of Fb and increasing concentrations of pla-
sminogen and antithrombin III [23]. Von Willebrand fac-
tor (VWF) has a crucial role in blood coagulation [26]. 
Increased plasma levels of VWF are observed in cardio-
vascular, neoplastic and connective tissue diseases, proba-
bly because of endothelium dysfunction, which leads to an 
increased risk of thrombosis [16]. The ARIC study confir-
med that VWF is a risk factor of ischaemic stroke [15]. It 
was found that FA supplementation decreases VWF con-
centrations [23]. C-reactive protein (CRP) levels rise in re-
sponse to inflammation. Some research suggest that indi-
viduals with elevated basal concentrations of CRP are at 
an increased risk of diabetes and cardiovascular disease 
[8,19]. Therefore CRP is not only an inflammation mar-
ker, but is also considered as a risk indicator for cardiova-
scular disease [7].
The aim of this study was to analyse the effect of folic acid 
supplementation on fibrinogen, von Willebrand factor and 
C-reactive protein plasma concentrations.
Streszczenie
  Wprowadzenie:  Kwas foliowy (FA) może opóźniać tworzenie się zmian miażdżycowych. W chorobach układu 
krążenia obserwuje się podwyższone poziomy czynnika von Willebranda (VWF) w osoczu, co 
zwiększa ryzyko zakrzepicy. Fibrynogen (Fb) jest dobrze udokumentowanym czynnikiem ryzy-
ka chorób układu krążenia. Celem badania była analiza wpływu suplementacji FA na osoczowe 
stężenia Fb, VWF i białka C-reaktywnego (CRP) u osób z czynnikami ryzyka miażdżycy.
 Materiał/Metody:  Do badania włączono 124 osoby rasy kaukaskiej (60 M, 64 K) z czynnikami ryzyka miażdży-
cy – wywiadem rodzinnym przedwczesnego niedokrwiennego udaru mózgu, z nadciśnieniem 
tętniczym, dyslipidemią, nadwagą i otyłością, nikotynizmem i niewielką aktywnością fizycz-
ną. Uczestnicy zostali poproszeni o przyjmowanie FA w niskiej dawce 0,4 mg/24 h przez trzy 
miesiące.
  Wyniki:  Po suplementacji FA zaobserwowano istotną redukcję stężeń VWF u kobiet (76,6 vs 72,3%; 
p=0,028) i u mężczyzn (75,5 vs 66,9%; p=0,001). Wśród kobiet i mężczyzn z dyslipidemią stę-
żenia VWF obniżyły się po suplementacji FA (odpowiednio 76,8 vs 69,6%; p=0,003 i 76,7 vs 
67,8%; p=0,001). Wśród kobiet i mężczyzn z BMI ≥25 kg/m2 stężenia VWF obniżyły się tylko 
u mężczyzn (77,6 vs 66,5%; p=0,001). U palących osobników płci męskiej i żeńskiej suplemen-
tacja FA skutkowała obniżeniem stężeń VWF (odpowiednio 82,5 vs 74,4%; p=0,012 i 76,6 vs 
69,5%; p=0,036).
  Dyskusja:  Wyniki naszego badania wskazują, że suplementacja FA wpływa na stężenia VWF u osób z czyn-
nikami ryzyka miażdżycy.
  Słowa kluczowe:	 miażdzyca	•	czynniki	krzepnięcia	•	CRP	•	fibrynogen	•	kwas	foliowy	•	hemostaza	•	czynnik	
von	Willebranda
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The study enrolled 124 adult Caucasian individuals (60 
males aged 20–39 and 64 females aged 19–39) with athe-
rosclerosis risk factors. A standard interview on the envi-
ronmental risk factors for atherosclerosis was performed 
and revealed the presence of family history of premature 
ischaemic stroke, arterial hypertension, dyslipidaemia, 
overweight and obesity, cigarette smoking and low phy-
sical activity among study participants. The inclusion 
criteria for the study group were: age ≥18 years, patien-
t’s informed consent granted, absence of concurrent in-
flammation, no hypolipidaemic or metabolism-modula-
ting agents, no administration of B-group vitamins or 
vitamin preparations within 6 months before the study 
(use of hypotensive agents and oral contraceptives did 
not constitute exclusion criteria), young age of parents 
at the moment of ischaemic stroke (fathers younger than 
55 years, mothers younger than 65 years) confirmed by 
means of computed tomography or magnetic resonance. 
The study involved an initial assessment through medi-
cal history taking, physical examination and blood ana-
lysis. Next, the participants were asked to take FA in the 
low dose of 0.4 mg/24 h for three months [24,29], after 
which a follow-up examination was performed, again 
through medical history taking, physical examination 
and blood analysis. Initially, FA supplementation was 
offered to 147 subjects, 23 of whom (15.6%) were exc-
luded in the course of the study due to non-complian-
ce (irregular taking of FA, stopping taking it altogether, 
or not reporting for the follow-up examination at the 
end of the treatment period). The study was approved 
by the Bioethics Committee of the Pomeranian Medical 
University in Szczecin, Poland.
Fasting blood for biochemistry was collected. The folic 
acid level was determined by an Abbott test kit (Abbott 
Laboratories, Chicago, Illinois, USA) using the ion cap-
ture method on an IMX immunochemical analyser (by 
Abbott). Total homocysteine (Hcy) was determined by 
high performance liquid chromatography (HPLC) using 
test kits from Bio-Rad, on a Hewlett-Packard analyser 
with a fluorescence detector. Fibrinogen level was de-
termined by the Clauss method on a Hemolab analyser, 
using bioMérieux test kits. The von Willebrand factor 
was measured by means of a miniVidas analyser (bio-
Mérieux) and enzyme-linked immunosorbent assay. 
High-sensitivity C-reactive protein (hsCRP) was measu-
red by the immunonephelometric method using a Dade-
Behring BN-100 analyser (Dade Behring Holding GmbH, 
Liederbach, Germany).
Statistical analysis was performed using the STATISTICA 
StatSoft Polska v.9.0 package (StatSoft Inc., Tulsa, 
Oklahoma, USA) and the examined parameters were first 
evaluated for normal distribution (Shapiro-Wilk test). The 
significance of statistical differences was assessed with the 
chi-square test, chi-square test with Yates correction or 
Fisher’s exact test. The paired Student t test was used for 
the comparison of mean values of measured parameters. 
The two-way analysis of variance (ANOVA) with statisti-
cal significance in the post hoc test (NIR) was carried out. 
The CRP values were subjected to logarithmic transforma-
tion. The significance level was set at p≤0.05.
results
Table 1 shows the characteristics of examined patients. Low 
physical activity was adopted according to the Drygas de-
finition [9]. Tables 2 and 3 show that low-dose FA supple-
mentation resulted in statistically significant elevation of 
FA levels in studied females (6.3 vs 12.5 ng/dL; p=0.001) 
and males (6.4 vs 11.4 ng/dL; p=0.001) and concomitantly, 
a decrease in Hcy levels (10.6 vs 8.3 µmol/L; p=0.001 and 
11.5 vs 9.3; p=0.001 respectively). There were no signifi-
cant differences in Fb concentrations before and after FA 
supplementation in both genders. A significant reduction 
in mean concentration for VWF in females (76.6 vs 72.3%; 
p=0.028) and in males (75.5 vs 66.9%; p=0.001) was ob-
served. There were no significant differences in CRP con-
centrations before and after FA supplementation in both 
genders. Tables 4 and 5 show that evaluation of FA sup-
plementation in women (n=43) and men (n=46) with dys-
lipidaemia revealed a significant decrease in VWF concen-
trations (76.8% vs 69.6%; p=0.003 and 76.7% vs 67.8%; 
p=0.001 respectively). Among females (n=19) and males 
(n=29) with BMI ≥25 kg/m2 the concentrations of VWF 
decreased after FA supplementation only in men (77.6% 
vs 66.5%; p=0.001). In female (n=24) and male smokers 
(n=21) supplementation of FA resulted in decrease of VWF 
concentrations (82.5% vs 74.4%; p=0.012 and 76.6% vs 
69.5%; p=0.036 respectively).
dIscussIon
The effect of low-dose FA supplementation (0.4 mg/24 h) 
on fibrinogen, von Willebrand factor and CRP concentra-
tions was evaluated in this study. FA supplementation re-
sulted in a significant decrease of VWF concentrations in 
analyzed individuals. Moreover, the decrease of VWF con-
centrations was especially marked in smoking or dyslipida-
emic women and in smoking or dyslipidaemic or overwe-
ight and obese men. FA supplementation had no effect on 
Fb and CRP concentrations in the studied group.
Fibrinogen induces reversible aggregation of erythrocy-
tes, reduces the fluidity of blood and affects clot forma-
tion through thrombocyte aggregation [6,13,27]. Fb also 
binds to leukocytes due to their surface receptors and acts 
Characteristics Study group
n=124
Age (years) 28.4±5.9
Females 51.6%
Family history of PIS 100.0%
Smokers 36.3%
Dyslipidaemia 71.7%
BMI >25 kg/m2 38.7%
Low physical activity 70.2%
Oral contraception (% of females) 23.4%
Table 1. Subjects’ characteristics
PIS – premature ischemic stroke; BMI – body mass index
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       -               -               -               -               -       as a ligand for ICAM-1 (intercellular adhesion molecu-
le-1) located on the thrombocytes and endothelium. This 
interaction leads to adhesion of platelets and leukocytes 
to the endothelial cells and plays a significant role in athe-
rothrombosis [12]. A meta-analysis of prospective clini-
cal trials regarding the effect of Fb on the cardiovascular 
incidents revealed that Fb concentrations were correlated 
with risk of death as a result of coronary heart disease, stro-
ke (both ischaemic and haemorrhagic) or other vascular 
causes [10]. We found no correlation between FA supple-
mentation and Fb concentrations. Liem et al. also reported 
a lack of impact of FA (0.5 mg/24 h) supplementation on 
Factor
Before supplementation After supplementation
p*
mean SD mean SD
Folic acid (ng/dL) 6.3 3.0 12.5 3.9 0.001
Hcy (µmol/L) 10.6 3.8 8.3 2.1 0.001
VWF (%) 76.6 23.0 72.3 22.0 0.028
Fibrinogen (g/L) 3.1 0.6 3.1 0.7 NS
CRP (mg/L) 0.3 1.0 0.2 1.0 NS
Table 2. The effect of three-month diet supplementation with folic acid on Fb, VWF and CRP concentrations in females (n=64)
* Student’s paired t-test. Hcy – homocysteine; VWF – von Willebrand factor; CRP – C-reactive protein
Factor
Before supplementation After supplementation
p*
mean SD mean SD
Folic acid (ng/dL) 6.4 2.8 11.4 3.0 0.001
Hcy (µmol/L) 11.5 3.9 9.3 1.8 0.001
VWF (%) 75.0 25.2 66.9 18.2 0.001
Fibrinogen (g/L) 2.7 0.6 2.8 0.6 NS
CRP (mg/L) 0.4 0.9 0.4 1.1 NS
Table 3. The effect of three-month diet supplementation with folic acid on Fb, VWF and CRP concentration in males (n=60)
* Student’s paired t-test. Hcy – homocysteine; VWF – von Willebrand factor; CRP – C-reactive protein
Parameter in 
females
Dyslipidaemia (n=43) BMI ≥25 kg/m2 (n=19) Smokers (n=24)
Before 
suppl.
After 
suppl. p Before 
suppl.
After 
suppl p Before 
suppl.
After 
suppl. p
VWF (%) 76.8 69.6 0.003 80.3 80.7 NS 82.5 74.4 0.012
Fb (g/L) 3.16 3.09 NS 3.4 3.48 NS 3.0 3.1 NS
CRP (mg/L) 0.16 0.14 NS 1.23 1.65 NS 0.83 0.89 NS
Table 4.   The effect of three-month supplementation with folic acid on VWF, Fb and CRP concentrations depending on dyslipidaemia (n=43), BMI 
≥25 kg/m2 (n=19) and smoking (n=24) in females
pANOVA with statistical significance in the post hoc test (NIR). VWF – von Willebrand factor; Fb – Fibrinogen; CRP – C-reactive protein
Parameter in 
males
Dyslipidaemia (n=46) BMI ≥25 kg/m2 (n=29) Smokers (n=21)
Before 
suppl.
After 
suppl. p Before 
suppl.
After 
suppl p Before 
suppl.
After 
suppl. p
VWF (%) 76.7 67.8 0.001 77.6 66.5 0.001 76.6 69.5 0.036
Fb (g/L) 2.76 2.85 NS 2.77 2.90 NS 2.79 2.6 NS
CRP (mg/L) 0.25 0.31 NS 1.53 1.38 NS 1.4 1.4 NS
Table 5.   The effect of three-month supplementation with folic acid on VWF, Fb and CRP concentrations depending on dyslipidaemia (n=46), BMI 
≥25 kg/m2 (n=29) and smoking (n=21) in males
pANOVA with statistical significance in the post hoc test (NIR). VWF – von Willebrand factor; Fb – Fibrinogen; CRP – C-reactive protein
Mierzecki A. et al. – Is there an effect of folic acid supplementation…
699  
       -               -               -               -               -       Fb concentrations [15]. The authors stated that low-dose 
folic acid supplementation in regard to cardiovascular risk 
should be treated with caution. However, two reports in-
dicate a beneficial effect of FA supplementation. Oral ad-
ministration of FA (10 mg/24 h) decreased Fb and VWF 
concentrations and increased plasminogen and antithrom-
bin III concentrations in studied subjects [23]. The second 
report showed a decrease of Fb concentrations and an in-
crease of antithrombin concentrations after FA supple-
mentation (dose of 5.0 or 10.0 mg/24 h) in patients with 
hyperhomocysteinaemia [22]. Mangoni et al. observed an 
anti-thrombotic effect of FA [20]. CRP along with Fb is 
a marker of an inflammatory response and is classified as 
an acute-phase protein. The role of CRP is binding to pho-
sphocholine on microbes and damaged cells and enhan-
cing phagocytosis by macrophages [31]. Therefore CRP 
takes part in the clearance of necrotic and apoptotic cells 
[25]. There are some reports on the association between 
FA supplementation and inflammatory markers. As in our 
study, some research carried out by other authors showed 
no effect of FA supplementation on CRP concentrations 
in analysed subjects [15,20,31].
Von Willebrand factor is a multimeric blood glycoprotein, 
produced by endothelial cells, subendothelial connective 
tissue and partly by megakaryocytes [26]. It is involved in 
primary haemostasis as an adhesive protein through bin-
ding platelets to the collagen and secondary haemostasis 
due to forming a complex with factor VIII, protecting it 
against proteolysis [26]. VWF is considered to be a mar-
ker of endothelial dysfunction in vascular disorders [16]. 
The ARIC study analysed VWF as an ischaemic stroke risk 
factor through comparison of the highest and the lowest 
quartile of VWF concentrations in analysed subjects. The 
relative risk of an ischaemic stroke, after amendments to 
the conventional risk factors, was 1.71 (without regarding 
CRP) and 1.21 (after correction for CRP) [11]. We obse-
rved a significant decrease of VWF concentrations among 
studied subjects. Our observations confirm the results ob-
tained by Mayer et al., who achieved a 6.8% reduction in 
VWF concentrations among individuals with high cardio-
vascular risk, after FA supplementation in the dose of 10 
mg/24 h [23]. However, it should be noted that we achie-
ved a similar reduction in VWF concentrations using a 25 
times lower dose of FA than Mayer et al. Moreover, we 
observed a significant reduction of VWF serum concen-
trations especially in subjects with dyslipidaemia, obese 
males and cigarette smoking individuals. The decrease of 
VWF levels was demonstrated probably because low do-
ses of FA improve vascular endothelium function, which 
is involved in the synthesis, storage and release of VWF. 
When endothelial cells are damaged, the VWF release is 
increased. Therefore VWF levels are useful as an atherosc-
lerosis/thrombosis indicator. Endothelial damage is secon-
dary to arterial hypertension, hyperlipidaemia, smoking, 
diabetes or metabolic disorders and results in activation 
of the coagulation cascade [26]. Hcy, levels of which are 
increased in those diseases, is linked to oxidation and en-
dothelial injury. Administration of FA improves endothe-
lial cell function through Hcy levels lowering and oxida-
tive stress reduction [23]. Nevertheless, not all authors 
have obtained similar results. Mangoni et al., Vermuelen 
et al. and Klerk et al., applying doses of 5.0 mg/24 h or 
0.8 mg/24 h, observed no correlation between FA supple-
mentation and VWF concentrations [14,20,30]. Reported 
differences are associated with studied subjects and me-
thods of FA supplementation. Mangoni et al. analysed a 
group which consisted of 100% smokers, while 36.3% of 
our group were smokers. Vermeuelen et al. supplemented 
not only FA, but also vitamin B6. Klerk applied FA du-
ring a 1-year period, but in our study the supplementation 
lasted for 12 weeks because of earlier reported observa-
tions that FA supplementation effects are noticeable from 
the 4th week of oral intake [24,29].
The results of our study suggest that there is an effect of 
folic acid supplementation on von Willebrand factor con-
centrations in subjects with atherosclerosis risk factors. 
However, to confirm this observation further studies are 
needed.
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